Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Feb 26:9:45.
doi: 10.3389/fonc.2019.00045. eCollection 2019.

Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma Receiving Immunomodulatory Therapy

Robert Frank Cornell  1 , Samuel Z Goldhaber  2 , Brian G Engelhardt  1 , Javid Moslehi  3 , Madan Jagasia  1 , Daryl Patton  4 , Shelton Harrell  1 , Robert Hall  1 , Houston Wyatt  1 , Greg Piazza  2
Affiliations

Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma Receiving Immunomodulatory Therapy

Robert Frank Cornell et al. Front Oncol. .

Abstract

Immunomodulatory drugs (IMiDs), including thalidomide, lenalidomide, and pomalidomide, have improved survival of patients with multiple myeloma (MM). However, these therapies are associated with an increased risk of venous thromboembolism (VTE). Apixaban has been approved for treatment of acute VTE and for risk reduction of recurrent VTE following initial therapy. In this phase IV single-arm study (NCT02958969), we aim to prospectively evaluate the safety and efficacy of apixaban for primary prevention of VTE in patients with MM. The primary efficacy objective of this trial is to determine the rate of symptomatic VTE, including deep vein thrombosis (DVT) and pulmonary embolism (PE), over 6 months. The primary safety objective is to determine the rate of major bleeding in MM patients receiving apixaban prophylaxis. If proven safe and effective, apixaban will emerge as a promising option for oral VTE prophylaxis in MM patients.

Keywords: Apixaban (Eliquis®); anticoagulation (AC); immunomodualtors; myeloma; venous thomboembolism.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Study management scheme.
See this image and copyright information in PMC

References

    1. Palumbo A, Anderson K. Multiple myeloma. New Eng J Med. (2011) 364:1046–60. 10.1056/NEJMra1011442 - DOI - PubMed
    1. Gandhi UH, Senapedis W, Baloglu E, Unger TJ, Chari A, Vogl D, et al. Clinical implications of targeting XPO1-mediated nuclear export in multiple myeloma. Clin Lymph Myeloma Leukemia. (2018) 18:335–45. 10.1016/j.clml.2018.03.003 - DOI - PubMed
    1. Li W, Cornell RF, Lenihan D, Slosky D, Jagasia M, Piazza G, et al. Cardiovascular complications of novel multiple myeloma treatments. Circulation (2016) 133:908–12. 10.1161/CIRCULATIONAHA.115.018351 - DOI - PubMed
    1. Li W, Garcia D, Cornell RF, Gailani D, Laubach J, Maglio ME, et al. Cardiovascular and thrombotic complications of novel multiple myeloma therapies: a review. JAMA Oncol. (2017) 3:980–8. 10.1001/jamaoncol.2016.3350 - DOI - PubMed
    1. Piazza G. Venous thromboembolism and cancer. Circulation (2013) 128:2614–8. 10.1161/CIRCULATIONAHA.113.002702 - DOI - PubMed